

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: AI/ML Innovations Inc. (the "Issuer").

Trading Symbol: AIML

Number of Outstanding Listed Securities: 34,930,270

Date: 5/5/2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued to advance its business operations on multiple fronts. Its majority owned subsidiary, Health Gauge, was active in developing additional business relationships and continued development work of its apps. The issuer's minority-owned subsidiary, Tech2Heal, also continued the development work on

its Remote Patient Monitoring Platform and additional strategic partnerships for its flagship Qookka mental wellness platform.

2. Provide a general overview and discussion of the activities of management.

During the month, management has been primarily engaged in the improvement of Health Gauge's technology, including the continued development work on upgrades to its mobile apps and cloud-based platform to improve efficiency and accuracy and to add new feature sets, along with FDA regulatory work for compliancy as a Class 2 Medical Device in the US and Canada. It also furthered its discussions with potential channel partners and other potential users of the HG technology.

Additionally, management of the Issuer was engaged in ongoing due diligence and discussions regarding other potential acquisitions.

3. Describe and provide details of any new products or services developed or offered.

None.

4. Describe and provide details of any products or services that were discontinued.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On April 12, 2022, the Company entered into an arm's length marketing service agreement with Octagon Media Corp which remains in effect until July 12, 2022. Octagon's subsidiary, Wall Street Reporter will provide coverage of AI/ML Innovations' news releases and produce video interviews for the Issuer.

The total aggregate consideration for the agreement includes - US\$25,000 per month for the 3-month engagement, and the Company will also grant Octagon Media Corp incentive stock options to purchase up to 500,000 common shares in the capital of the Company at an exercise price of CAD\$0.20 per share, for a 12-month period. 50% of the options vest immediately and the balance vest on the 6-month anniversary of the engagement.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the

disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number issued	Details	Use of Proceeds
options	500,000 @ \$0.20 per share	Incentive options to an arms-length service provider	N/A

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There is a growing awareness and acceptance amongst the public, healthcare providers, insurers/payors, and regulators towards the use of digital and virtual healthcare in general, with mental healthcare making up an increasing component

of that. This trend is expected to continue at double digit growth rates globally for the next several years. Its acceptance has been expedited by the CV-19 pandemic as patients were discouraged from face-to-face medical intervention in all but the most dire of circumstances. The general public has grown to understand the ease and convenience of digital healthcare as a result and healthcare payors understand that the deployment of digital health solutions both improves outcomes and reduces costs. Governments across Europe are implementing laws requiring payors to cover the cost of digital mental health therapy to the same extent as conventional methods.

Certificate Of Compliance


The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated 5/5/2022

Tim Daniels

Name of Director or Senior
Officer



Signature

Executive Chairman

Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer		April 2022	YY/MM/D
AI/ML Innovations Inc.			22/5/5
Issuer Address			
Suite 203, 645 Fort St.			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
Victoria, BC V8W 1G2		(778) 405-0882	
Contact Name	Contact Position	Contact Telephone No.	
Tim Daniels	Director	250 483-5650	
Contact Email Address	Web Site Address		
tim.daniels@aiml-innovations.com	aiml-innovations.com		